- Home
- TYRA vs AIO Comparison
TYRA vs AIO Comparison
Compare TYRA & AIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TYRA
- AIO
- Stock Information
- Founded
- TYRA 2018
- AIO 2019
- Country
- TYRA United States
- AIO United States
- Employees
- TYRA N/A
- AIO N/A
- Industry
- TYRA Biotechnology: Pharmaceutical Preparations
- AIO Finance/Investors Services
- Sector
- TYRA Health Care
- AIO Finance
- Exchange
- TYRA Nasdaq
- AIO Nasdaq
- Market Cap
- TYRA 812.7M
- AIO 760.3M
- IPO Year
- TYRA 2021
- AIO N/A
- Fundamental
- Price
- TYRA $15.36
- AIO $23.34
- Analyst Decision
- TYRA Strong Buy
- AIO
- Analyst Count
- TYRA 5
- AIO 0
- Target Price
- TYRA $31.00
- AIO N/A
- AVG Volume (30 Days)
- TYRA 599.6K
- AIO 141.5K
- Earning Date
- TYRA 11-07-2024
- AIO 01-01-0001
- Dividend Yield
- TYRA N/A
- AIO 9.05%
- EPS Growth
- TYRA N/A
- AIO N/A
- EPS
- TYRA N/A
- AIO N/A
- Revenue
- TYRA N/A
- AIO N/A
- Revenue This Year
- TYRA N/A
- AIO N/A
- Revenue Next Year
- TYRA N/A
- AIO N/A
- P/E Ratio
- TYRA N/A
- AIO N/A
- Revenue Growth
- TYRA N/A
- AIO N/A
- 52 Week Low
- TYRA $10.60
- AIO $15.09
- 52 Week High
- TYRA $29.60
- AIO $20.25
- Technical
- Relative Strength Index (RSI)
- TYRA 34.38
- AIO 61.50
- Support Level
- TYRA $15.04
- AIO $22.18
- Resistance Level
- TYRA $16.51
- AIO $22.99
- Average True Range (ATR)
- TYRA 0.94
- AIO 0.52
- MACD
- TYRA 0.04
- AIO -0.01
- Stochastic Oscillator
- TYRA 11.68
- AIO 69.07
About TYRA Tyra Biosciences Inc.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology The Company's in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNAPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. Its lead product candidate is TYRA 300, an FGFR3 selective inhibitor with an initial focus on patients with metastatic urothelial carcinoma of the bladder and urinary tract (mUC).
About AIO Virtus Artificial Intelligence & Technology Opportunities Fund of Beneficial Interest
Virtus Artificial Intelligence & Technology Opportunities Fund is a diversified, limited-term closed-end management investment company. The fund's investment objective is to provide total return through a combination of current income, current gains, and long-term capital appreciation.